mimivax.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Disallow: /wp-admin/ Allow: | ||
Meta Tags
| Title | Homepage - |
| Description | Disrupting cancer through SurVaxM Pipeline SurVaxM Clinical Trials About Leadership Team News Contact Menu Pipeline SurVaxM Clinical Trials About Leadership Team News Contact Pipeline SurV |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 198.71.233.15 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
mimivax.com Valuation
|
US$3,253,883
Last updated: 2023-05-06 23:49:57
mimivax.com has Semrush global rank of 3,252,823. mimivax.com has an estimated worth of US$ 3,253,883, based on its estimated Ads revenue. mimivax.com receives approximately 375,448 unique visitors each day. Its web server is located in United States, with IP address 198.71.233.15. According to SiteAdvisor, mimivax.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$3,253,883 |
| Daily Ads Revenue | US$3,004 |
| Monthly Ads Revenue | US$90,108 |
| Yearly Ads Revenue | US$1,081,291 |
| Daily Unique Visitors | 25,030 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| mimivax.com. | A | 600 | IP: 198.71.233.15 |
| mimivax.com. | NS | 3600 | NS Record: ns45.domaincontrol.com. |
| mimivax.com. | NS | 3600 | NS Record: ns46.domaincontrol.com. |
| mimivax.com. | MX | 3600 | MX Record: 20 mx2-us1.ppe-hosted.com. |
| mimivax.com. | MX | 3600 | MX Record: 10 mx1-us1.ppe-hosted.com. |
| mimivax.com. | TXT | 600 | TXT Record: v=spf1 a:dispatch-us.ppe-hosted.com include:spf.protection.outlook.com -all |
| mimivax.com. | TXT | 600 | TXT Record: google-site-verification=s55L1-vvuUvNmxMQKzBLfhUFrDWBLsRu8w0u-VCt8fk |
| mimivax.com. | TXT | 600 | TXT Record: NETORGFT2120759.onmicrosoft.com |
HtmlToTextCheckTime:2023-05-06 23:49:57
| Pipeline SurVaxM Clinical Trials About Leadership Team News Contact Menu Pipeline SurVaxM Clinical Trials About Leadership Team News Contact Pipeline SurVaxM Clinical Trials About Leadership Team News Contact Disrupting cancer through SurVaxM immunotherapy At MimiVax, our mission is to disrupt cancer. We are dedicated to improving survival and sending hope to cancer patients CONTACT US OUR pipeline News and Events “Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma” -J ournal of Clinical Oncology 41, no. 7 (March 01, 2023) 1453-1465. click to access journal MimiVax Announces Positive Final Data from the Phase 2A Study of SurVaxM for Newly Diagnosed Glioblastoma Published Today in the Journal of Clinical Oncology The current study found that 51% of nGBM patients receiving SurVaxM had survived at least 2 years and 41% had survived 3 years, considerably higher rates than has been seen historically from standard care. MimiVax is pleased to announce the |
mimivax.com Whois Information
Domain Name: MIMIVAX.COM Registry Domain ID: 1645269117_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2021-03-14T18:00:55Z Creation Date: 2011-03-13T23:21:13Z Registry Expiry Date: 2022-03-13T23:21:13Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS45.DOMAINCONTROL.COM Name Server: NS46.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-14T21:42:31Z <<< |